Author

M. B. Robers

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Assay:proteomics· 4 Organism:human· 3 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

J. D. Vasta· 3 shared C. A. Zimprich· 2 shared C. R. Corona· 2 shared M. T. Beck· 2 shared A. Lewis· 1 shared A. Lyczek· 1 shared A. M. Rangwala· 1 shared A. Michaud· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCell Biology

J. D. Vasta

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Development of Cell Permeable NanoBRET Probes for the Measurement of PLK1 Target Engagement in Live Cells

X. Yang, J. L. Smith, M. T. Beck, J. M. Wilkinson, A. Michaud, J. D. Vasta, M. B. Robers, T. M. Willson

The paper develops a NanoBRET probe to measure PLK1 target engagement in live cells and evaluates its use with known PLK inhibitors.

bioRxiv · Feb 25, 2023 · PreprintCell Biology

Small Molecule Modulation of the Archetypal UbiB protein COQ8

N. H. Murray, A. Lewis, C. R. M. Asquith, J. P. R. Pabon, Z. Fang, N. Ptak, R. W. Smith, J. D. Vasta, C. A. Zimprich, C. R. Corona, M. B. Robers, C. A. Bingman, M. L. Gross, K. Henzler-Wildman, D. J. Pagliarini

The paper develops small molecule inhibitors and activators for COQ8A, a UbiB family protein, using crystallography, NMR, and mass spectrometry to modulate its function in CoQ biosynthesis.

bioRxiv · Mar 22, 2022 · PreprintBiochemistry

KRAS is vulnerable to reversible switch-II pocket engagement in cells

J. D. Vasta, D. M. Peacock, Q. Zheng, J. A. Walker, Z. Zhang, C. A. Zimprich, M. R. Thomas, M. T. Beck, B. F. Binkowski, C. R. Corona, M. B. Robers, K. M. Shokat

The paper investigates the accessibility of the switch-II pocket in various KRAS mutants using NMR and a cellular engagement assay, showing it is accessible with non-covalent ligands regardless of GDP state.

Nature Chemical Biology · Mar 21, 2022Peer-reviewedCancer Biology

Mutation in Abl kinase with altered drug binding kinetics indicates a novel mechanism of imatinib resistance

A. Lyczek, B.-T. Berger, A. M. Rangwala, Y. Paung, J. Tom, H. Philipose, J. Guo, S. K. Albanese, M. B. Robers, S. Knapp, J. D. Chodera, M. A. Seeliger

The paper identifies a mutation in Abl kinase that causes imatinib resistance through altered drug dissociation kinetics rather than reduced binding affinity.

bioRxiv · Jun 28, 2021Biochemistry